| Document |
Document Title |
|
WO/2024/061665A1 |
The invention relates to isoxazoline compounds of formula I wherein the variables have the meanings as defined in the specification, to compositions comprising them, to active compound combinations comprising them, and to their use for p...
|
|
WO/2024/061118A1 |
The present invention provides a macrocyclic nitrogen-containing crown ether compound represented by formula (I) and use thereof as a protein kinase inhibitor.
|
|
WO/2024/061178A1 |
Disclosed are a compound containing a five-membered heterocycle, a preparation method therefor, an application thereof, an agricultural composition, and a method for preventing and controlling invertebrate pests. The present invention pr...
|
|
WO/2024/061340A1 |
This disclosure provides compounds of Formula 1 or 8, compositions comprising the same, and methods of using the same, including uses in modulating NAMPT and treating various diseases and conditions that are responsive to NAMPT activation.
|
|
WO/2024/059951A1 |
This invention provides compound having a structure of Formulas I-VI. Uses of such compounds for treatment of various indications that would benefit from modulation of the androgen receptor, including prostate cancer. Also provided are m...
|
|
WO/2024/059317A1 |
Provided are YAP/TAZ-TEAD oncoproteins inhibitors of Formula (I), or a stereoisomer, and/or a pharmaceutically acceptable salt, and/or solvate thereof, pharmaceutical compositions thereof, and methods of treatment.
|
|
WO/2024/057021A1 |
The present disclosure relates to a novel class of bifunctional molecules that are useful in a targeted or selective degradation of a protein.
|
|
WO/2024/059659A1 |
Provided herein are compounds of formula (I): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, n, Y1, Y2, X1, X2, X3, Q1, and Ra are as defined elsewhere herein. Also provid...
|
|
WO/2024/057001A1 |
The present invention relates to compounds of Formula (I) that may act as agonists of retinoic acid receptor alpha (RAR-α) and/or retinoic acid receptor beta (RAR-β). The invention also relates to pharmaceutical compositions comprising...
|
|
WO/2024/059249A1 |
The present disclosure provides compounds of Formula I: (I), or an N- oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: A, Y, m, n, p, R1, R2, R3, R3a, R4, R5, R6, R7, and Z are as described he...
|
|
WO/2024/059010A1 |
The present application relates to compounds of Formula (A), as defined herein, and pharmaceutically acceptable salts thereof, as well as processes for preparing compounds of Formula (A), and pharmaceutically acceptable salts thereof. Th...
|
|
WO/2024/057958A1 |
The present invention provides: a material which enables a photoelectric conversion element for imaging to achieve high sensitivity; and a photoelectric conversion element for imaging using this material. The present invention uses a m...
|
|
WO/2023/159307A9 |
Disclosed are compounds and pharmaceutically acceptable salts of formula (I), which feature either a N-(1H-pyrazol-3-yl)pyridin-2-amine or a N-(1H-pyrazol-3-yl)pyrimidin-4-amine core structure. These compounds may be used in the treatmen...
|
|
WO/2024/059781A1 |
Described are 6-aryl isoindolin-1-ones as negative allosteric modulators of metabotropic glutamate receptor 2 (mGlu2), pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating ...
|
|
WO/2024/057020A1 |
This invention relates to compounds that can be used to treat viral infections. The compounds are papain-like protease (PLpro) inhibitors.
|
|
WO/2024/059524A1 |
The invention provides pyrazolylcarboxamide compounds, pharmaceutical compositions, their use for inhibiting mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), and their use in the treatment of a disease or condi...
|
|
WO/2024/059186A1 |
The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.The present invention provides isoquinoline derivatives of for...
|
|
WO/2024/051816A1 |
Provided is a bicyclic PRMT5 inhibitor, which is a compound having a structure represented by formula (I). Further provided are a preparation method for the compound and use of the compound in regulating PRMT5 activity or treating PRMT5-...
|
|
WO/2024/051812A1 |
The present invention relates to a novel amide compound or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing same, and a use thereof as a KIF18A inhibitor in prevention or treatment of related diseases.
|
|
WO/2024/050825A1 |
A substituted cyclic compound as represented by formula (I) and having a selective inhibitory effect on MLKL, or a pharmaceutically acceptable salt, a stereoisomer, a solvate or a prodrug thereof, a pharmaceutical composition containing ...
|
|
WO/2024/052701A1 |
Provided are compounds of the Formula I, and salts, hydrates and solvates thereof: I wherein Q1, R1, Ra, Rb, Rc, Rd, Re, A1 and A2 are each as defined in the specification. The compounds are inhibitors of Casein Kinase 2 alpha (CK2α) an...
|
|
WO/2024/054071A1 |
The present invention relates to a novel compound having histone deacetylase 6 (HDAC6) inhibitory activity, a method for preparing the same, and uses thereof. The novel compound according to the present invention, a stereoisomer thereof ...
|
|
WO/2024/051778A1 |
Provided herein are compounds having a Formula II-4, or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compounds in inhibiting PI3K in a cell, or in treati...
|
|
WO/2024/053316A1 |
The present invention addresses the problem of providing a novel compound, which binds to extracellular vesicles and enables size measurement by liquid chromatography, etc., an extracellular vesicle staining agent and a fluorescent stain...
|
|
WO/2024/052702A1 |
Provided are compounds of the Formula I, and salts, hydrates and solvates thereof: wherein RL, L and RR, and any groups associated therewith, are each as defined in the specification. The compounds are inhibitors of Casein Kinase 2 alpha...
|
|
WO/2024/051702A1 |
The present invention relates to a compound used as an inhibitor of a CDK4 kinase and use thereof. Specifically, the compound of the present invention has a structure represented by formula (I), wherein the definitions of each group and ...
|
|
WO/2024/054876A1 |
The present disclosure relates to bifunctional compounds that cause the degradation of LRRK2; pharmaceutical compositions comprising the compounds; and methods of treating disorders associated with LRRK2, including Parkinson's Disease.
|
|
WO/2024/054832A1 |
Provided herein are compounds that act as molecular glues, inducing degradation of CK1α or CK1α/GSPT1, and pharmaceutically acceptable derivatives thereof. Also provided are pharmaceutical compositions containing the compounds and meth...
|
|
WO/2024/054591A1 |
Provided herein are bifunctional compounds, which find utility as modulators of Rapidly Accelerated Fibrosarcoma (Raf, such as c-Raf, A-Raf, and/or B-RAF).
|
|
WO/2024/051766A1 |
The present disclosure relates to a compound of formula (I) or a salt, an enantiomer, a diastereomer, an isotope-enriched analogue, a solvate, a prodrug or a polymorph thereof, and the use thereof. Further provided in the present disclos...
|
|
WO/2023/227737A9 |
The present invention relates to compounds of Formula (I), (I) or an agronomically acceptable salt of said compounds wherein A1, A2, A3, X1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein. The invention further relates to herbicidal...
|
|
WO/2024/050297A1 |
Described herein are compounds that are inhibitors of autophagy and their use in the treatment of disorders such as cancers.
|
|
WO/2024/046890A1 |
The present invention relates to compounds of Formula (I), or an agronomically acceptable salt of said compounds wherein A, Q, R1, R2, R3 and m are as defined herein. The invention further relates to herbicidal compositions which compris...
|
|
WO/2024/049977A1 |
Provided herein are substituted indole compounds. In certain embodiments, the compounds are inhibitors of the alternative pathway of the complement system, and in particular, inhibitors of complement factor B (CFB). Also provided are com...
|
|
WO/2024/047135A1 |
Provided herein are compounds identified as inhibitors of KRAS protein activity that can be used to treat various diseases and disorders, such as cancer.
|
|
WO/2024/049829A2 |
A pharmaceutical composition comprising a compound a binding pocket adjacent the wedge domain of an intracellular portion or fragment of the receptor protein tyrosine phosphatase (RPTP) IIb cell adhesion molecules (e.g., PTPμ) and that ...
|
|
WO/2024/046409A1 |
The present invention relates to a heterocyclic compound, a preparation method therefor, and a pharmaceutical use thereof. Specifically, the present invention relates to a heterocyclic compound as shown in general formula (I), a preparat...
|
|
WO/2024/046253A1 |
Provided in the present invention are a sodium channel regulator and the use thereof. The sodium channel regulator of the present invention has a brand-new structure and has an excellent in-vitro inhibitory effect on Nav 1.8. The compoun...
|
|
WO/2024/044848A1 |
The present application relates to indazole derivatives of general Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptors in a cell, as well as to treating...
|
|
WO/2024/048778A1 |
The present invention relates to an aryltetrahydropyridine compound represented by formula (1) or a salt thereof. [In formula (1), Q represents Q-1, etc.; J represents J-1, etc.; G represents G-1, etc.; R1 represents a halo(C1-C6)alkyl, ...
|
|
WO/2024/041397A1 |
Provided 4-pyrazolyl-N-heteroarylpyrimidin-2-amine compounds as potent TYK2/JAK1/JAK2 inhibitors with low systemic exposures when applied topically. Thus, these compounds, and compositions are useful as topical treatment of dermatologica...
|
|
WO/2024/044344A1 |
The invention provides pyridinylsulfonamide compounds, pharmaceutical compositions, their use for inhibiting mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), and their use in the treatment of a disease or condi...
|
|
WO/2024/044730A1 |
The invention provides pyrazolylsulfonamide compounds, pharmaceutical compositions, their use for inhibiting mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), and their use in the treatment of a disease or condi...
|
|
WO/2024/042007A1 |
The invention relates to substituted bicycles of the general formula I, and the use of the compounds of the present invention for the treatment and/or prevention of hyperproliferative diseases and disorders in mammals, especially humans,...
|
|
WO/2024/040768A1 |
Disclosed in the present invention are a 5-pyridine-1H-indazole compound, a pharmaceutical composition, and a use. The structure of the compound is represented by formula I or II, and also comprised are an isomer or pharmaceutically acce...
|
|
WO/2024/042043A1 |
This invention relates to a synthetic method for the preparation of compound (1) and precursors thereof. Compound (1) is prepared via reaction of isoxazole (2) with phenylether (R)-3-ONa.
|
|
WO/2024/042146A2 |
The present invention provides covalent fluorescent probes for cannabinoid receptor 2 ("CB2") having the general formula (I) wherein X, n, p, and R1 to R4 are as described herein, compositions including the compounds, processes of manufa...
|
|
WO/2024/044757A1 |
The present disclosure provides compounds and compositions that are useful as MYC protein modulators and methods of using the same for treating MYC-mediated diseases or disorders.
|
|
WO/2024/039689A1 |
Provided herein are compounds of formula (I) that modulate RMB39 and methods of using the compounds in RMB39-associated disorders, such as cancer (e.g., renal cell carcinoma).
|
|
WO/2024/038282A1 |
The present invention provides compounds of formula (I): Formula (I) compositions comprising such compounds; the use of such compounds in medicine; and methods of treating patients with such compounds; wherein A, W, V, Z, Y and B are as ...
|
